Abstract:
La presente invención se refiere a un compuesto 1 o 2 o composición que lo comprende. La presente invención también se refiere a un procedimiento para la obtención de un compuesto 1 o 2, así como la utilización de los mismos para la detección de GHB en bebidas y en orina. También se incluye un equipo o kit para utilizar en la detección de GHB en bebidas y en orina.
Abstract:
This invention relates to novel compounds and compositions thereof, useful in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).
Abstract:
Cyanine compounds represented by the general formula (I): (I) wherein R 1 and R 2 are each independently hydrogen, hydroxy, halogeno, nitro, cyano, an organic group having 1 to 30 carbon atoms, or a group represented by the general formula (II), (II') or (III); R 3 and R 4 are each independently hydrogen, an organic group having 1 to 30 carbon atoms, or a substituent represented by the general formula (III); R 1 and R 2 may be united to form a ring structure; R 3 and R 4 may be united to form a heterocycle; N-R 3 together with the adjacent methylene group of the polymethylene chain may form a heterocycle; X is oxygen, sulfur, selenium, -CR 5 R 6 -, -NH- or -NY j -; R 5 and R 6 are each independently an organic group having 1 to 30 carbon atoms or a substituent represented by the general formula (II), (II') or (III), or alternatively R 5 and R 6 may be united to form a ring structure; Y j is an organic group having 1 to 30 carbon atoms or a group represented by the general formula (III); Z 0 is an organic group having 1 to 10 carbon atoms; n is 1 or 2; r is 2 to 8; An q- is a q-valent anion; q is 1 or 2; and p is a coefficient making the charge neutral.
Abstract translation:由通式(I)表示的花青化合物:(I)其中R 1和R 2各自独立地为氢,羟基,卤代,硝基,氰基,有机基团 具有1至30个碳原子,或由通式(II),(II')或(III)表示的基团; R 3和R 4各自独立地为氢,具有1至30个碳原子的有机基团或由通式(III)表示的取代基; R 1和R 2可以结合形成环结构; R 3和R 4可以结合形成杂环; N-R 3与聚亚甲基链的相邻亚甲基一起可以形成杂环; X是氧,硫,硒,-CR 5,...,-NH-或-NY - R 5和R 6各自独立地为具有1至30个碳原子的有机基团或由通式(II),(II')或(III)表示的取代基 )或者可选地R 5和R 6可以结合形成环结构; Y为具有1至30个碳原子的有机基团或由通式(III)表示的基团; Z 0是具有1至10个碳原子的有机基团; n为1或2; r为2〜8; q-是q价阴离子; q为1或2; p是使电荷中性的系数。
Abstract:
The present invention relates to ion channel modulating agents. More particularly, the present invention relates to a particular class of chemical compounds that has proven useful as modulators of SKCa, IKCa and BKCa channels. In further aspects, the present invention relates to the use of these SK/IK/BK channel modulating agents for the manufacture of medicaments, and pharmaceutical compositions comprising the SK/IK/BK channel modulating agents. The SK/IK/BK channel modulating agents of the invention are useful for the treatment or alleviation of diseases and conditions associated with the SK/IK/BK channels.
Abstract translation:本发明涉及离子通道调节剂。 更具体地,本发明涉及已被证明可用作SKCa,IKCa和BKCa通道调节剂的特定类别的化合物。 在其它方面,本发明涉及这些SK / IK / BK通道调节剂在制备药物中的用途,以及包含SK / IK / BK通道调节剂的药物组合物。 本发明的SK / IK / BK通道调节剂可用于治疗或减轻与SK / IK / BK通道相关的疾病和病症。
Abstract:
The present invention relates to new substituted benzoxa(thia)zoles, methods for producing the compounds, agents containing these compounds, and the use thereof as biologically active compounds, in particular for fighting harmful microorganisms in plant and material protection.
Abstract:
Die vorliegende Erfindung betrifft neue Cycloalkylamidbenzoxa(thia)zole, Verfahren zum Herstellen dieser Verbindungen, Mittel enthaltend diese Verbindungen, sowie deren Verwendung als biologisch aktive Verbindungen, insbesondere zur Bekämpfung von schädlichen Mikroorganismen im Pflanzenschutz und im Materialschutz.
Abstract:
The invention provides compounds and pharmaceutical compositions thereof, which are useful for modulating G protein-coupled receptor 20 (GPR20), and methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated GPR20.
Abstract:
The invention includes tissue factor (TF) blocking compounds and methods of treatment and pharmaceutical compositions that utilize or comprise one or more of such compounds. Compounds of the invention are particularly useful for treating or prophylaxis of undesired thrombosis.
Abstract:
The present invention relates to novel alkanoyl-substituted heterocyclic derivatives which are cysteine protease inhibitors; the pharmaceutically acceptable salts and N-oxides thereof; their uses as therapeutic agents and the methods of their making; according to Formula (I) in which: A comprises a heteromonocyclic ring containing 5 to 6 ring member atoms or a fused heteropolycyclic ring system containing 8 to 14 ring member atoms, wherein each ring contains 5 to 7 ring member atoms, X is a ring member carbon atom and each ring member atom other than X is a carbon atom or a heteroatom, with the proviso that (i) at least one ring member atom is a heteroatom and (ii) when A is a heteromonocyclic radical containing 5 ring member atoms, no more than two of the ring member atoms comprising A are heteroatoms; n is 0, 1, 2 or 3; X is =C- or -CH-; X is a bond or a divalent group of Formula (a) or (b); R - R = as in the application.
Abstract translation:本发明涉及新型烷酰基取代的杂环衍生物,它们是半胱氨酸蛋白酶抑制剂; 其药学上可接受的盐和N-氧化物; 其作为治疗剂的用途及其制备方法; 根据式(I),其中:A包含含有5至6个环成员原子的杂单环或含有8至14个环成员原子的稠合杂多环系,其中每个环含有5至7个环成员原子,X 1, 是环成员碳原子,除X 1之外的每个环成员原子是碳原子或杂原子,条件是(i)至少一个环原子是杂原子,和(ii)当A是异单环 含有5个环成员原子的基团,不超过两个包含A的环成员原子是杂原子; n为0,1,2或3; X 1是= C-或-CH-; X 2为式(a)或(b)的键或二价基团; R 1 -R 8 =如申请中所述。